Interleukin-1 gene complex polymorphisms in systemic sclerosis patients with severe restrictive lung physiology

Human Immunology

Volumn 68, Issue 7, 2007, Pages 603-609

  Beretta, Lorenzo ^a   Bertolotti, Francesca ^a   Cappiello, Francesca ^a   Barili, Morena ^a   Masciocchi, Michela ^a   Toussoun, Karen ^a   Caronni, Monica ^a   Scorza, Raffaella ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Interleukin 1; Interstitial lung disease; Single nucleotide polymorphism; Systemic sclerosis

Indexed keywords

ADENINE; AUTOANTIBODY; CYTOSINE; DNA TOPOISOMERASE; DNA TOPOISOMERASE ANTIBODY; GAMMA INTERFERON; GUANINE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; PREDNISONE; THYMINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CONFIDENCE INTERVAL; COVARIANCE; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; FORCED EXPIRATORY VOLUME; GENDER; GENOTYPE; HUMAN; ITALY; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RESPIRATORY FAILURE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC SCLEROSIS;

ADULT; BRONCHOALVEOLAR LAVAGE FLUID; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; ITALY; LUNG DISEASES, OBSTRUCTIVE; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; REGRESSION ANALYSIS; SCLERODERMA, SYSTEMIC;

EID: 34250307119     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2007.03.005     Document Type: Article

References (41)

1. White B. Interstitial lung disease in scleroderma. Rheum Dis Clin North Am 29 (2003) 371
2. Wells A.U., Hansell D.M., Corrin B., Harrison N.K., Goldstraw P., Black C.M., and du Bois R.M. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax 47 (1992) 738
3. Munger J.S., Huang X., Kawakatsu H., Griffiths M.J., Dalton S.L., Wu J., Pittet J.F., Kaminski N., Garat C., Matthay M.A., Rifkin D.B., and Sheppard D. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 99 (1999) 319
4. White B., Moore W.C., Wigley F.M., Xiao H.Q., and Wise R.A. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 132 (2000) 947
5. Atamas S.P., and White B. Cytokine regulation of pulmonary fibrosis in scleroderma. Cytokine Grow Factor Rev 14 (2003) 537
6. Pan L.H., Othani H., Yamauchi K., and Nagura H. Co-expression of TNFa and IL1b in human acute polmonary fibrotic diseases; an immunohistochemical analysis. Pathol Int 4 (1996) 1
7. Yucesoy B., Vallyathan V., Landsittel D.P., Simeonova P., and Luster M.I. Cytokine polymorphisms in silicosis and other pneumoconioses. Mol Cell Biochem 234-235 (2002) 219
8. Kawaguchi Y., McCarthy S.A., Watkins S.C., and Wright T.M. Autocrine activation by interleukin-1a induces the fibrogenic phenotypes of systemic sclerosis fibroblasts. J Rheumatol 31 (2004) 1946
9. Hussein M.R., Hassan H.I., Hofny E.R., Elkholy M., Fatehy N.A., Abd Elmoniem A.E., Ezz El-Din A.M., Afifi O.A., and Rashed H.G. Alterations of mononuclear inflammatory cells, CD4/CD8+ T cells, interleukin 1beta, and tumour necrosis factor alpha in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis. J Clin Pathol 58 (2005) 178
10. Dinarello C.A. Interleukin 1 and interlukin-1 antagonism. Blood 77 (1991) 1627
11. Nicklin M.J., Barton J.L., Nguyen M., FitzGerald M.G., Duff G.W., and Kornman K. A sequence-based map of the nine genes of the human IL-1 cluster. Genomics 79 (2002) 718
12. Hulkkonen J., Laippala P., and Hurme M. A rare allele combination of the interleukin-1 gene complex is associated with high interleukin-1 beta plasma levels in healthy individuals. Eur Cytokine Netw 11 (2000) 251
13. Pociot F., Molvig J., Wogensen L., Worsaae H., and Nerup J. A TaqI polymorphism in the human interleukin-1β (IL-1β) gene correlates with IL-1β secretion in vitro. Eur J Clin Invest 22 (1992) 396
14. Danis V.A., Millington M., Hyland V.J., and Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 99 (1995) 303
15. Dominici R., Cattaneo M., Malferrari G., Archi D., Mariani C., Grimaldi L.M., and Biunno I. Cloning and functional analysis of the allelic polymorphism in the transcription regulatory region of interleukin-1 alpha. Immunogenetics 54 (2002) 82
16. Hollegaard M.V., and Bidwell J.L. Cytokine gene polymorphism in human disease: on-line databases, Supplement 3. Genes Immunol 7 (2006) 269
17. Haukim N., Bidwell J.L., Smith A.J., Keen L.J., Gallagher G., Kimberly R., Huizinga T., McDermott M.F., Oksenberg J., McNicholl J., Pociot F., Hardt C., and D'Alfonso S. Cytokine gene polymorphism in human disease: on-line databases, supplement 2. Genes Immunol 3 (2002) 313
18. Cullup H., and Stark G. Interleukin-1 polymorphisms and graft-vs-host disease. Leukocyte Lymphoma 46 (2005) 517
19. Whyte M., Hubbard R., Meliconi R., Whidborne M., Eaton V., Bingle C., Timms J., Duff G., Facchini A., Pacilli A., Fabbri M., Hall I., Britton J., Johnston I., and Di Giovine F. Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms. Am J Respir Crit Care Med 162 (2000) 755
20. Louie L.G., Silver E.W., Direskeneli G.S., et al. Worldwide variation in cytokine genes. In: Hansen J.A., and Dupont B. (Eds). HLA 2004: immunobiology of the human MHC (2004), IHWG Press, Seattle, WA Proceedings of the 13th International Histocompatibility Workshop and Congress
21. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutics Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23 (1980) 581
22. LeRoy E.C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger Jr. T.A., Rowell N., and Wollheim F. Scleroderma (systemic sclerosis): classification, subset and pathogenesis. J Rheumatol 15 (1998) 202
23. White B., Bauer E.A., Goldsmith L.A., Hochberg M.C., Katz L.M., Korn J.H., and The American College of Rheumatlogy Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. Semin Arthritis Rheum 38 (1995) 351
24. Bayer P.M., Bauerfeind S., Bienvenu J., Fabien N., Frei P.C., Gilburd B., Heide K.G., Hoier-Madsen M., Meroni P.L., Monier J.C., Monneret G., Panzeri P., Shoenfeld Y., Spertini F., and Wiik A. Multicenter evaluation study on a new HEp2 ANA screening enzyme immune assay. J Autoimmun 13 (1999) 89
25. Steen V.D., and Medsger Jr. T.A. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43 (2000) 2437
26. Hoffmann S.C., Stanley E.M., Darrin Cox E., Craighead N., DiMercurio B.S., Koziol D.E., Harlan D.M., Kirk A.D., and Blair P.J. Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. Transplantation 72 (2001) 1444
27. Virelizier J.L., and Arenzana-Seisdedos F. Immunological functions of macrophages and their regulation by interferons. Med Biol 63 (1985) 149
28. Dinarello C.A., Cannon J.G., Wolff S.M., Bernheim H.A., Beutler B., Cerami A., Figari I.S., Palladino Jr. M.A., and O'Connor J.V. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 163 (1986) 1433
29. Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M., and O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 147 (1991) 3815
30. Turner D.M., Williams D.M., Sankaran D., Lazarus M., Sinnott P.J., and Hutchinson I.V. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24 (1997) 1
31. Tseng L.H., Chen P.J., Lin M.T., Singleton K., Martin E.G., Yen A.H., Martin P.J., and Hansen J.A. Simultaneous genotyping of single nucleotide polymorphisms in the IL-1 gene complex by multiplex polymerase chain reaction-restriction fragment length polymorphism. J Immunol Methods 267 (2002) 151
32. Uboldi de Capei M.U., Dametto E., Fasano M.E., Rendine S., and Curtoni E.S. Genotyping for cytokine polymorphisms: allele frequencies in the Italian population. Eur J Immunogenet 30 (2003) 5
33. Ostojic P., and Damjanov N. Different clinical features in patients with limited and diffuse cutaneous systemic sclerosis. Clin Rheumatol 25 (2006) 819 2006 28 Apr
34. Steen V.D. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35 (2005) 35
35. Kawaguchi Y., Harigai M., Suzuki K., Hara M., Kobayashi K., Ishizuka T., Matsuki Y., Tanaka N., and Nakamura H. Interleukin 1 receptor on fibroblasts from systemic sclerosis patients induces excessive functional responses to interleukin 1 beta. Biochem Biophys Res Commun 190 (1993) 154
36. Luzina I.G., Atamas S.P., Wise R., Wigley F.M., Xiao H.Q., and White B. Gene expression in bronchoalveolar lavage cells from scleroderma patients. Am J Respir Cell Mol Biol 26 (2002) 549
37. Beretta L., Cappiello F., Bertolotti F., Barili M., and Scorza R. T-889C IL-1α promoter polymorphism influences the response to oral cyclophosphamide in scleroderma patients with alveolitis. Clin Rheumatol 26 (2007) 88
38. Hutyrova B., Lukac J., Bosak V., Buc M., du Bois R., and Petrek M. Interleukin-1-alpha single nucleotide polymorphism associated with systemic sclerosis. J Rheum 31 (2004) 81
39. McBride W.H., Hoon D.B., Jung T., Naungayan J., Nizze A., and Morton D.L. Cyclophosphamide-induced alterations in human monocyte functions. J Leukocyte Biol 42 (1987) 659
40. Snyder D.S., and Unanue E.R. Corticosteroids inhibit murine macrophage Ia expression and interleukin 1 production. J Immunol 129 (1982) 1803
41. Ommen E.S., Winston J.A., and Murphy B. Medical risk in living kidney donors: absence of proofs is not proof of absence. Clin J Am Soc Nephrol 1 (2006) 885